Share on StockTwits

Biota Pharmaceuticals (NASDAQ:BOTA) EVP Joseph M. Patti bought 10,000 shares of the stock in a transaction that occurred on Monday, June 30th. The stock was purchased at an average cost of $2.86 per share, for a total transaction of $28,600.00. Following the completion of the transaction, the executive vice president now directly owns 68,241 shares of the company’s stock, valued at approximately $195,169. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.

Biota Pharmaceuticals (NASDAQ:BOTA) opened at 3.07 on Friday. Biota Pharmaceuticals has a 52-week low of $2.35 and a 52-week high of $7.07. The stock has a 50-day moving average of $2. and a 200-day moving average of $4.60. The company’s market cap is $107.7 million.

Biota Pharmaceuticals (NASDAQ:BOTA) last released its earnings data on Tuesday, May 6th. The company reported $0.09 EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.28) by $0.37. Analysts expect that Biota Pharmaceuticals will post $-0.22 EPS for the current fiscal year.

Separately, analysts at TheStreet downgraded shares of Biota Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, May 30th.

Biota Pharmaceuticals, Inc, formerly Nabi Biopharmaceuticals, is an anti-infective drug development company, with key expertise in respiratory diseases, particularly influenza.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.